<p>Moderna（纳斯达克代码：MRNA - 获取免费报告）的股票在周四发布给投资者的研究报告中被威廉·布莱尔的研究分析师重申了 “市场表现” 评级，RTT 新闻报道。</p>
<ul>
<li>MarketBeat 周回顾 – 03/10 - 03/14</li>
</ul>
<p>MRNA 还受到其他几份报告的关注。美国银行在 2 月 11 日的研究报告中将 Moderna 的目标价格从 41.00 美元下调至 34.00 美元，并对该公司设定了 “表现不佳” 的评级。巴克莱在 2 月 18 日的报告中将 Moderna 的评级从 “增持” 下调至 “持平”，并将该公司的目标价格从 111.00 美元下调至 45.00 美元。阿根廷证券在 12 月 18 日的研究报告中将 Moderna 的评级从 “买入” 下调至 “持有”。贝伦贝格银行在 1 月 16 日的研究报告中将 Moderna 的目标价格从 33.00 美元上调至 42.00 美元，并给予该公司 “持有” 评级。最后，Leerink Partners 在 1 月 16 日的报告中将 Moderna 的目标价格从 31.00 美元下调至 27.00 美元，并对该公司设定了 “减持” 评级。四位分析师对该股票给予了卖出评级，十六位分析师给予了持有评级，三位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价格为 58.70 美元。</p>
<p><strong>获取我们对 Moderna 的最新股票分析</strong></p>
<h2>Moderna 股票下跌 1.1%</h2>
<ul>
<li>Moderna：首席执行官刚刚以 500 万美元购买股票的四个关键原因</li>
</ul>
<p>周四交易时段，MRNA 的股票下跌 0.29 美元，报 24.90 美元。该公司交易了 1,485,493 股，相比其平均交易量 7,207,112 股。该公司的市值为 96.3 亿美元，市盈率为-2.69，贝塔值为 2.23。该公司的 50 日移动平均线为 31.10 美元，200 日移动平均线为 40.37 美元。Moderna 的 52 周低点为 23.15 美元，52 周高点为 170.47 美元。</p>
<h2>机构投资者对 Moderna 的看法</h2>
<p>机构投资者最近调整了对该公司的持股。Allworth Financial LP 在第四季度将其在 Moderna 的持股增加了 17.3%。Allworth Financial LP 现在拥有 1,901 股该公司的股票，价值 73,000 美元，此前在该期间内增持了 281 股。霍华德资本管理公司在第四季度将其在 Moderna 的股份增加了 3.1%。霍华德资本管理公司现在拥有 9,994 股该公司的股票，价值 416,000 美元，此前在该期间内增持了 297 股。伊塔乌联合银行在第四季度将其在 Moderna 的持股增加了 51.2%。伊塔乌联合银行现在拥有 1,013 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 343 股。英联邦证券服务公司在第四季度将其在 Moderna 的股份增加了 0.5%。英联邦证券服务公司现在拥有 74,520 股该公司的股票，价值 3,099,000 美元，此前在该期间内增持了 345 股。最后，拉尔森金融集团在第四季度将其在 Moderna 的持股增加了 39.1%。拉尔森金融集团现在拥有 1,266 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 356 股。75.33% 的股票由机构投资者持有。</p>
<h2>Moderna 公司简介</h2>
<p>（获取免费报告）</p>
<ul>
<li>Moderna：2025 年投资者的世代机会</li>
</ul>
<p>Moderna, Inc.是一家生物技术公司，专注于发现、开发和商业化信使 RNA 治疗和疫苗，用于治疗传染病、免疫肿瘤、罕见病、自身免疫病和心血管疾病，业务遍及美国、欧洲及国际市场。其呼吸道疫苗包括 COVID-19、流感和呼吸道合胞病毒、Spikevax 和 hMPV/PIV3 疫苗；潜伏疫苗包括巨细胞病毒、埃布斯坦 - 巴尔病毒、单纯疱疹病毒、水痘带状疱疹病毒和人类免疫缺陷病毒疫苗；公共卫生疫苗包括寨卡、尼帕病毒、猴痘疫苗；以及传染病疫苗，如莱姆病和诺如病毒疫苗。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过 Moderna</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>关税豁免为台湾半导体的反弹铺平了道路</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>缓解关税：三只股票将从美元走弱中获益</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>博通与苹果的关系：人工智能机会与关税风险相遇</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Moderna 吗？</h2>
<p>在考虑 Moderna 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Moderna 并不在名单上。</p>
<p>虽然 Moderna 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRNA

<p>威廉·布莱尔（William Blair）重申了对 Moderna（纳斯达克代码：MRNA）股票的 “市场表现” 评级。该股票在不同分析师中面临着混合评级， 美国银行将其目标价格下调至 34 美元，并给予 “跑输大盘” 评级。其他公司也调整了他们的评级和目标价格。目前，Moderna 的共识评级为 “持有”，目标价格为 58.70 美元。该股票下跌 1.1%，报 24.90 美元，机构持股比例达到 75.33%</p>

<p>Moderna (NASDAQ:MRNA - Get Free Report)'s stock had its &#34;market perform&#34; rating restated by research analysts at William Blair in a research note issued to investors on Thursday,RTT News reports.</p>
<div class="lb-trans"><p>Moderna（纳斯达克代码：MRNA - 获取免费报告）的股票在周四发布给投资者的研究报告中被威廉·布莱尔的研究分析师重申了 “市场表现” 评级，RTT 新闻报道。</p>
</div><ul>
<li>MarketBeat Week in Review – 03/10 - 03/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 03/10 - 03/14</li>
</ul>
</div><p>MRNA has been the subject of several other reports. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an &#34;underperform&#34; rating for the company in a research report on Tuesday, February 11th. Barclays downgraded Moderna from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and reduced their target price for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus downgraded Moderna from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, December 18th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, January 16th. Finally, Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an &#34;underweight&#34; rating for the company in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Hold&#34; and a consensus price target of $58.70.</p>
<div class="lb-trans"><p>MRNA 还受到其他几份报告的关注。美国银行在 2 月 11 日的研究报告中将 Moderna 的目标价格从 41.00 美元下调至 34.00 美元，并对该公司设定了 “表现不佳” 的评级。巴克莱在 2 月 18 日的报告中将 Moderna 的评级从 “增持” 下调至 “持平”，并将该公司的目标价格从 111.00 美元下调至 45.00 美元。阿根廷证券在 12 月 18 日的研究报告中将 Moderna 的评级从 “买入” 下调至 “持有”。贝伦贝格银行在 1 月 16 日的研究报告中将 Moderna 的目标价格从 33.00 美元上调至 42.00 美元，并给予该公司 “持有” 评级。最后，Leerink Partners 在 1 月 16 日的报告中将 Moderna 的目标价格从 31.00 美元下调至 27.00 美元，并对该公司设定了 “减持” 评级。四位分析师对该股票给予了卖出评级，十六位分析师给予了持有评级，三位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价格为 58.70 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Moderna</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Moderna 的最新股票分析</strong></p>
</div><h2>Moderna Stock Down 1.1 %</h2>
<div class="lb-trans"><h2>Moderna 股票下跌 1.1%</h2>
</div><ul>
<li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna：首席执行官刚刚以 500 万美元购买股票的四个关键原因</li>
</ul>
</div><p>Shares of MRNA traded down $0.29 during trading hours on Thursday, hitting $24.90. 1,485,493 shares of the company were exchanged, compared to its average volume of 7,207,112. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -2.69 and a beta of 2.23. The firm's fifty day moving average is $31.10 and its 200 day moving average is $40.37. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $170.47.</p>
<div class="lb-trans"><p>周四交易时段，MRNA 的股票下跌 0.29 美元，报 24.90 美元。该公司交易了 1,485,493 股，相比其平均交易量 7,207,112 股。该公司的市值为 96.3 亿美元，市盈率为-2.69，贝塔值为 2.23。该公司的 50 日移动平均线为 31.10 美元，200 日移动平均线为 40.37 美元。Moderna 的 52 周低点为 23.15 美元，52 周高点为 170.47 美元。</p>
</div><h2>Institutional Investors Weigh In On Moderna</h2>
<div class="lb-trans"><h2>机构投资者对 Moderna 的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its holdings in Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after acquiring an additional 281 shares during the period. Howard Capital Management Inc. grew its stake in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the period. Itau Unibanco Holding S.A. increased its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after buying an additional 345 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in shares of Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after buying an additional 356 shares in the last quarter. 75.33% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Allworth Financial LP 在第四季度将其在 Moderna 的持股增加了 17.3%。Allworth Financial LP 现在拥有 1,901 股该公司的股票，价值 73,000 美元，此前在该期间内增持了 281 股。霍华德资本管理公司在第四季度将其在 Moderna 的股份增加了 3.1%。霍华德资本管理公司现在拥有 9,994 股该公司的股票，价值 416,000 美元，此前在该期间内增持了 297 股。伊塔乌联合银行在第四季度将其在 Moderna 的持股增加了 51.2%。伊塔乌联合银行现在拥有 1,013 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 343 股。英联邦证券服务公司在第四季度将其在 Moderna 的股份增加了 0.5%。英联邦证券服务公司现在拥有 74,520 股该公司的股票，价值 3,099,000 美元，此前在该期间内增持了 345 股。最后，拉尔森金融集团在第四季度将其在 Moderna 的持股增加了 39.1%。拉尔森金融集团现在拥有 1,266 股该公司的股票，价值 53,000 美元，此前在上个季度增持了 356 股。75.33% 的股票由机构投资者持有。</p>
</div><h2>Moderna Company Profile</h2>
<div class="lb-trans"><h2>Moderna 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Moderna: A Generational Opportunity for Investors in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna：2025 年投资者的世代机会</li>
</ul>
</div><p>Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.</p>
<div class="lb-trans"><p>Moderna, Inc.是一家生物技术公司，专注于发现、开发和商业化信使 RNA 治疗和疫苗，用于治疗传染病、免疫肿瘤、罕见病、自身免疫病和心血管疾病，业务遍及美国、欧洲及国际市场。其呼吸道疫苗包括 COVID-19、流感和呼吸道合胞病毒、Spikevax 和 hMPV/PIV3 疫苗；潜伏疫苗包括巨细胞病毒、埃布斯坦 - 巴尔病毒、单纯疱疹病毒、水痘带状疱疹病毒和人类免疫缺陷病毒疫苗；公共卫生疫苗包括寨卡、尼帕病毒、猴痘疫苗；以及传染病疫苗，如莱姆病和诺如病毒疫苗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Moderna</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Moderna</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>关税豁免为台湾半导体的反弹铺平了道路</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>缓解关税：三只股票将从美元走弱中获益</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>博通与苹果的关系：人工智能机会与关税风险相遇</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MRNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Moderna Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Moderna 吗？</h2>
</div><p>Before you consider Moderna, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Moderna 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Moderna 并不在名单上。</p>
</div><p>While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Moderna 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Moderna（纳斯达克股票代码：MRNA）被 William Blair 评为市场表现